Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB500 Combinations in Small Cell Lung Cancer
NCT07296809Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SKB500 in small cell lung cancer (SCLC), sponsored by Kelun-Biotech. Started Jan 2026; status: recruiting.
02
Drugs
SKB500
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07296809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07296809.